Physician profile
Michael S Katz
NPI 1336215037
$6,247.28
in general payments reported to CMS, 2019-2025
36 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $236 · 2021: $841 · 2022: $1,177 · 2023: $1,043 · 2024: $1,192 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883 · Education: $53.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.61 |
| Education | $53.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $885.54 | 2019-2025 | Farxiga, Evusheld, Lokelma |
| Amgen INC. | $748.81 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $626.14 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $408.24 | 2019-2025 | Veltassa, Korsuva |
| Novo Nordisk INC | $393.42 | 2021-2025 | Rybelsus, Ozempic |
| Fresenius USA Marketing, INC. | $376.68 | 2019-2024 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $353.01 | 2021-2025 | |
| Travere Therapeutics, INC. | $350.58 | 2019-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $322.73 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $286.94 | 2020-2025 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $179.03 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $130.86 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $127.68 | 2019-2024 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.84 | 2023-2024 | Jardiance, Synjardy |
| Akebia Therapeutics INC | $104.73 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $98.69 | 2019-2024 | Benlysta |
| Alexion Pharmaceuticals, INC. | $85.06 | 2021-2024 | Ultomiris |
| Daiichi Sankyo INC. | $77.79 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $70.69 | 2022-2024 | Amvuttra, Oxlumo |
| Nuwellis, INC. | $61.82 | 2019-2021 | |
| Ardelyx, INC. | $58.44 | 2024-2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $55.25 | 2019 | |
| Scpharmaceuticals INC. | $54.22 | 2025 | |
| Ani Pharmaceuticals, INC. | $52.02 | 2022-2024 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $32.62 | 2022-2023 | Prevymis |
| Cormedix INC. | $32.13 | 2024 | Defencath |
| Takeda Pharmaceuticals U.S.A., INC. | $24.18 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $19.97 | 2021 | |
| Amicus Therapeutics, INC. | $19.31 | 2021 | |
| Genentech USA, INC. | $19.01 | 2025 | Gazyva |
| Invivyd INC | $18.94 | 2025 | Pemgarda |
| Amag Pharmaceuticals, INC. | $17.44 | 2019 | |
| Abbvie INC. | $17.09 | 2021 | |
| Amarin Pharma, INC. | $16.88 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.50 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.